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CARDIOMYOPATHY 
Prognosis in Hypertrophic Cardiomyopathy 
Observed in a Large Clinic Population 
Marcel J. Kofflard, MD, David J. Waldstein, MD, Jeroen Vos, MD, and Folkert J. ten Cate, MD 
Overall annual cardiac mortality in hypertrophic 
cardiomyopathy (HC) has been reported to be be 
tween 2 and 4%, although these numbers are pri- 
marily from retrospective studies of patients rf+ 
ferred to large research institutions. A clinic popu- 
lation of 113 patients with HC was prospectively 
studied to assess cardiac mortality in the overall 
group and in selected subgroups commonly 
thought to be at high risk for sudden death. The 
mean age at diagnosis was 37 + 16 years. During 
follow-up, there were 11 cardiac and 2 noncardiac 
deaths. The annual cardiac mortality was 1% (95% 
confidence interval 0.2-1.6%). Because of the 
small number of deaths, relative risk for cardiac 
death was not significantly different in the pres- 
ence of young age (130 years), family history of 
HC and sudden death, history of syncope or previ- 
ous cardiac arrest, or both, ventricular tachycardia 
on 24hour Holter monitoring, or septal myotomy/ 
myectomy for refractory symptoms and oufflow 
tract obstruction. It is concluded that HC has a rel- 
atively benign prognosis (1% annual cardiac mop 
tality) that is 2 to 4 times less than that previous- 
ly reported. 
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H ypertrophic cardiomyopathy (HC) is notorious for an increased risk of untimely death,tp3 but its actual prognosis is poorly defined. Previous 
studies reported overall annual mortality rates between 
2 and 4%.p10 These rates for the most part are based 
on hospitalized patients referred to large research institu- 
tions and probably tell a bleaker story than actually ex- 
ists for the general population of patients with HC, as 
suggested by a recent study by Spirit0 et al.] 1 These 
investigators followed a small number of outpatients 
with HC and found no case of sudden death or clinical 
deterioration over 3 to 6 years. 
Recent progress in electrophysiology12~13 and genet- 
ics14,15 has enabled investigators to identify selected pa- 
tients with particularly high risk for sudden death. Be- 
fore such highly technical and invasive tests are used in 
all patients with HC, a more accurate assessment of the 
overall prognosis in this disease is needed. Since 1970, 
we have followed a large number of patients at our HC 
clinic, representing the complete spectrum of the disease 
in regard to clinical presentations and treatment modal- 
ities. In our experience with these patients, we have 
found a remarkably low incidence of cardiac death. 
METHODS 
Patient selection: Patients in the HC clinic at the 
Thoraxcenter of Academic Hospital “Dijkzigt” general- 
ly are in 1 of the following 4 groups: (1) those diag- 
nosed in our hospital or outpatient clinics, (2) those 
transferred from outlying hospitals for advanced care, 
(3) outpatients referred from the community for advice 
and follow-up, and (4) self-referred family members of 
patients. 
Patients with identifiable causes of left ventricular 
hypertrophy, such as valvular aortic stenosis and uncon- 
trolled systemic hypertension, are not followed in the 
HC clinic and are not included in this study. 
Between 1970 and 1990, 113 patients were examined 
initially and at yearly intervals. Before 1979, the diag- 
nosis of HC was based on clinical parameters alone; 
after 1979, it was based on the echocardiographic tind- 
ing of a nondilated, hypertrophied left ventricle (any 
wall thickness >15 mm) in the absence of known caus- 
es of left ventricular hypertrophy.16 For children, 
ventricular hypertrophy was diagnosed in relation to 
published standards for height and weight.t7 
At the time of the initial visit, clinical characteristics 
including age at diagnosis of HC, family history of HC 
or sudden death in a first-degree relative, or both, histo- 
ry of syncope or sudden death, symptoms and New York 
Heart Association functional class were recorded. Phys- 
ical examination and baseline laboratory studies were 
performed, including M-mode and 2 dimensional echo- 
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TABLE I Baseline Characteristics of Patients with Hypertrophic 
Cardiomyopathy 
Patients 
Male/female 
Mean age (years) 
First visit 
Diagnosis 
Family history 
HC 
HC and SD 
History 
Syncope 
Cardiac arrest 
Symptoms 
Dyspnea 
Angina 
Palpitations 
NYHA functional class 
II 
Ill 
IV 
Therapy 
p blockers 
Calcium antagonists 
p blockers and calcium antagonists 
Antiarrhythmics 
LVOT gradient 
(at rest and/or provocation) 
z 50mm Hg 
Number (%I 
113 
60/53 
38 + 15 (range 12-76) 
37 + 16 (range 5-71) 
+ 54 (48%) 
0 35 (31%) 
- 24(21%) 
+ 40 (35%) 
0 52 (46%) 
- 21(19%) 
24 (21%) 
1 (1%) 
49 (43%) 
37 (33%) 
34 (30%) 
57 (50%) 
40 (36%) 
16 (14%) 
0 (0%) 
49 (43%) 
17 (15%) 
6 (5%) 
4 (3%) 
+ 38 (34%) 
- 68 (60%) 
0 7 (6%) 
HC = hypettrophic cardiomyopathy: LVOT = left ventricular outilow tract; NYHA = 
New York Heart Association; SD = sudden death; + = present; 0 = absent; - = 
unknown or not available. 
cardiography (as well as Doppler echocardiography after 
1985), and 24-hour ambulatory electrocardiographic 
monitoring when possible. Invasive hemodynamic and 
angiographic studies were performed only in patients 
with symptoms refractory to medical therapy who were 
potential surgical candidates. Surgery was recommend- 
ed if a peak left ventricular outflow tract gradient >50 
mm Hg at rest or with provocation was found. 
Followup: Patients were assessed on a yearly basis 
or more frequently, as indicated. All patients were fol- 
lowed exclusively by 1 physician (FJtC). 
Follow-up information on patients who moved out of 
Rotterdam was obtained from their private cardiologists. 
In cases of death, cause was determined by death cer- 
t&ate or autopsy when available, or by questioning of 
relatives or physicians involved in the patient’s care. 
Cardiac death was de-lined as death from myocardial 
infarction, congestive he& failure or arrhythmia, or sud- 
den death. Sudden death was assumed to be cardiac, and 
was defined as a witnessed death within 1 hour after the 
onset of symptoms or an unwitnessed death in a subject 
known to be alive and functioning normally 24 hours 
before.18 Episodes of successfully resuscitated cardiac 
arrest during follow-up were classified as cardiac death 
for the purposes of analysis. 
Statistics Survival estimates and 95% conlidence 
intervals were calculated according to the Kaplan-Meier 
method. The yearly mortality rate was calculated on the 
basis of all available follow-up time. To assess risk’fac- 
tors for cardiac death, univariate analysis was performed 
using the Cox regression model. For each indicator, the 
relative risk and 95% cotidence interval are reported. 
RESULTS 
Baseline characteristics: Cl&al characteristics of 
the 113 study patients (60 male and 53 female) at the 
time of the initial visit are presented in Table I. The 
mean age at presentation to our institution was 38 + 15 
years (range 12 to 76). Forty-three patients were aged 
130 years, and 6 patients were >65 years at the time of 
diagnosis. Fifty-four patients reported history of HC in 
21 first-degree relative, of whom 40 patients also re- 
ported a family history of sudden death at a young age 
(~40 years). Seven patients reported multiple sudden 
deaths in the family. No patient had family history of 
sudden death in the absence of HC. Twenty-four patients 
had syncope at presentation. One patient had a wit- 
nessed cardiac arrest and was successfully resuscitated. 
Reported symptoms included dyspnea in 49 patients, 
exertional angina in 37, and palpitations in 34. Fifty- 
seven patients were asymptomatic or had trivial symp- 
toms (New York Heart Association functional class I), 
40 were mildly symptomatic (class II), and 16 were 
moderately symptomatic (class III). No patient had New 
York Heart Association class n! 
Baseline medications included p blockers in 49 pa- 
tients, calcium antagonists in 17, both p blockers and 
calcium antagonists in 6, and antiarrhythmics in 4. 
The diagnosis of HC was coniirmed by 2-dimension- 
al echocardiography in all patients.19 Mean left ventric- 
ular wall thickness was 22 * 4 mm (range 15 to 40). 
Systolic anterior motion of the mitral valve was present 
in 64 patients. Left ventricular outflow tract obstruction 
>50 mm Hg at rest or with provocation was present in 
38 patients, as determined by Doppler echocardiography 
or cardiac catheterization, or both. Of 98 patients who 
had at least one 24-hour Holter monitor, 37 had 21 
episode of ventricular tachycardia (23 consecutive ven- 
tricular beats) recorded; none of these had sustained 
(>30 seconds) ventricular tachycardia. Holter recordings 
were generally obtained without discontinuation of med- 
ications. 
Followup data: No patient was lost to follow-up, 
and information was obtained in all surviving patients 
within 6 months of January 1990. Mean follow-up was 
7 k 6 years (range 1 to 19). 
During the follow-up period, 32 patients underwent 
myotomy/myectomy. One patient underwent concomitant 
mitral valve replacement for significant mitral valve 
regurgitation, and 3 underwent concomitant coronary 
artery bypass grafting for significant coronary artery 
disease. No patient had intraoperative placement of a 
permanent pacemaker or automatic implantable cardio- 
verter-defibrillator device; however, 4 patients needed 
permanent pacemakers after surgery. There was 1 peri- 
operative death, a patient with a preoperative gradient of 
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145 mm Hg and class II symptoms, who died of in- 
tractable congestive heart failure 21 days after surgery. 
Three surgical patients died suddenly in late follow-up 
at a mean of 5 years after surgery. 
During the follow-up period, 12 patients died and 1 
was successfully resuscitated from cardiac arrest, which 
in this study is considered a cardiac death. Two patients 
died of noncardiac causes: 1 at age 53 years from carci- 
noma of the lung, and 1 at age 76 from a cerebrovascu- 
lar accident. In the latter patient, a cardiac source of 
cerebral embolus was considered unlikely. The remain- 
ing 11 deaths were cardiac, of which 9 were sudden by 
delined criteria, including the 3 surgical patients and the 
1 cardiac arrest survivor. One patient, the perioperative 
patient previously described, died from congestive heart 
who died at home of an undetermined but presumably 
cardiac cause. One patient who died had proven coro- 
nary artery disease. 
The mean age at cardiac death was 47 * 18 years 
(range 26 to 80). The annual cardiac mortality in this 
population was 1% (95% conlidence interval 0.2 to 
1.8%). Figure 1 shows the Kaplan-Meier survival curve 
for patients free from cardiac death. 
For the purposes of analysis, patients were divided 
according to known or suspected risk factors for sudden 
death, including young age, family history of both HC 
and sudden death, history of syncope or sudden death, 
or both, and presence of ventricular tachycardia on 24- 
hour Holter monitoring.8,13,2S23 No statistically signifi- 
cant difference in risk of cardiac death was found in any 
failure. -The remaining death was in an go-year-old man subgroup (Table II). 
TABLE II Cardiac Death in Selected Subgroups of Patients with Hypertrophic 
Cardiomyopathy 
Cardiac Follow-Up 
Subgroup Number Deaths (years) RR (Cl) 
Total 113 11 7-t5 
(range l-19) 
Age I 30 years 
+ 43 5 8?5 1.36 (0.44-4.18) 
0 70 6 726 
FH of HC and SD 
+ 40 3 7+6 0.65 (0.17-2.44) 
0 52 6 725 
21 2 925 
Syncope and/or cardiac arrest 
+ 31* 4 926 1.51 (0.48-4.81) 
0 82 7 725 
VT on Halter 
+ 37 2 8~5 0.55 (0.12-2.58) 
0 61 6 826 
- 15 3 423 
Surgery 
+ 32 4 8+6 1.45 (0.45-4.61) 
0 81 7 725 
*Includes 7 patients with syncope duringfollow-up. 
Cl = 95% confidence intetval: FH = family history: RR = relative risk compared with patients in whom clinical feature IS 
absent; VT = ventricular tachycardla; other abbreviations as in Table I. 
FIGURE 1. Cardiac survival of 113 pb 
tients with hypertrophic cardiomyopathy. 
Numbers above horizontal axis refer to 
numbers of patients at each follow-up 
period. Vertical bars indicate 95% conf& 
dence intervals. 
‘oo% ; 
113 90 77 59 51 36 29 21 11 1 0% 
0 2 4 6 8 IO 12 14 16 18 20 
Time (year) 
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TABLE III Comparison of Clinical Features of Patients in Different Prognosis Studies 
Number 
Follow-Up 
(years) 
Mean 
Age 
(years) 
NYHA Class 
III or IV 
LVOT 
Gradient 
Present* Syncope FH of SD Surgery 
Annual 
Mortality (%) 
Swan et al4 
Hardarson et al5 
Shah et al6 
McKenna et al7 
Maron et ala 
Spirit0 et alI1 
Romeo et aI9 
Seiler et allo 
Present study 
85 
119 
190 
254 
99 
25 
125 
139 
113 
4.0 
4.6 
5.2 
6.0 
3.0 
4.4 
7.6 
8.9 
7.3 
- 11 
- 17 
69 
34 22 
38 18 
44 1 
34 78 
37 - 
37 16 
75 - 
30 
93 51 
139 49 
54 - 
5 0 
44 43 
- - 
38 31 
22 3.5t 
22 3.57 
58 3.4 
57 33 5.9$/2.6§ 
15 2.3 
0 0.0 
15 0 3.4 
- 79 2.411/3.61 
40 32 1.0 
*Number of patients with a “significant”gradient (definition varies among investigators). 
tEstimated from data. 
$Patlents aged < 15 years. 
~p;$;~;~b,l5 years. 
IMedical patients. 
Abbreviations as in Tables I and II. 
DISCUSSION 
This study is the lirst to report a benign prognosis 
for a large, relatively nonselected population of patients 
with HC. In this population of 113 patients, only 11 died 
from cardiac causes during an average follow-up of 7 
years, yielding an annual cardiac mortality rate of only 
1%. Previous prognosis studies reported overall annual 
cardiac mortality rates of 2 to 4%,4-7,9Jo with annual 
mortality rates up to 8.6% in selected high-risk sub- 
groups (Table III). 7,8J3 In contrast to those previous 
studies, the present study is both prospective and all- 
inclusive; the analysis does not exclude patients who are 
asymptomatic, do not have outflow tract gradients or 
have had cardiac surgery. 
All patients in this study were treated by the same 
physician according to the following flexible guidelines: 
initial trial of B blockers for relief of symptoms, if pres- 
ent; switch to calcium antagonists if symptoms persist; 
and surgical therapy for those with medically refractory 
symptoms in whom a significant outflow gradient is 
shown at cardiac catheterization. Ant&rhythmic thera- 
py was used very infrequently. We believe this thera- 
peutic algorithm, although not unique to our institution, 
may have conferred a survival benefit in these patients. 
Of 32 patients who underwent myotomylmyectomy 
during follow-up, there was only 1 perioperative death 
Equally good surgical results were obtained by Seiler et 
allo who recently reported only 1 perioperative death in 
79 surgical patients. This is in sharp contrast to previ- 
ous surgical series that reported operative mortality rates 
as high as 31%4-7 and to current estimated rates of 5 to 
8%.’ The present data show a relatively good prognosis 
for patients surviving surgery, as do previous stud- 
ies,6,7Jo although absolute protection against late sudden 
death does not occur. 
Other investigators have reported favorable progno- 
ses in specific subgroups of patients with HC, including 
the elderly,24 the nonobstructed, and those with apical 
hypertrophy. 26 Only recently was the overall experience 
in a general HC clinic reported: Spirit0 et all’ found no 
cases of cardiac death or deterioration in 25 outpatients, 
although the follow-up period was brief (mean 4.4 
years) and the patient cohort small. 
As Spirit0 et al” point out, and we believe correct- 
ly, selection bias has likely led to misrepresentation of 
the true prognosis in HC. They note that most patients 
in previous studies were hospitalized at 1 of 2 national 
referral centers. By inference, those patients are sicker 
and therefore have fatal complications more often than 
do those such as ours. However, it is difficult to prove 
the effect of selection bias, because a correlation be- 
tween presenting clinical features and risk of subsequent 
death has not been shown in HC,~J~S~O,~~ with the possi- 
ble exception of prior cardiac event7J3 and class IV dys- 
pnea.5 Although those 2 clinical features are rare in the 
present study, they are uncommon in other studies as 
well (Table III). 
Because of the low incidence of cardiac death in this 
population, we were unable to delineate statistically sig- 
nificant risk factors for this outcome. The clinical fea- 
tures commonly believed to confer an increased risk of 
sudden death include young age, strong family history 
of sudden death, previous history of syncope or cardiac 
arrest, and ventricular tachycardia on 24-hour Holter 
monitor, especially when associated with symp- 
toms.6-8J3,2”3 Recent genetic and electrophysiologic 
studies indentified new risk factors for sudden death, 
including particular chromosomal abnormalities14,‘5 and 
the presence of inducible sustained ventricular tachycar- 
dia.13 However, the present results suggest that applying 
genetic analysis and electrophysiologic testing to the 
general population of patients with HC is unjustified. 
With an annual cardiac mortality of 1% in HC, such 
expensive and invasive studies should be reserved only 
for the few patients known by history to be at ex- 
ceptionally high risk of sudden death. 
These findings also have important implications for 
the counseling of patients with HC. Although it is still 
necessary to inform affected patients and their relatives 
of the potential for sudden untimely death, physicians 
no longer need to paint an unduly bleak picture. The 
actual risk of dying in this disease is 2 to 4 times less 
than that previously reported. With further advances in 
the detection and treatment of patients at high risk for 
sudden death, true prognosis in HC can only be expect- 
ed to improve. 
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